You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT JAMA
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 260 No. 23, December 16, 1988 TABLE OF CONTENTS
  JAMA
  •  Online Features
  State of the Art/Review
 This Article
 •References
 •Full text PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Similar articles in JAMA
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Use and Abuse of Benzodiazepines

Issues Relevant to Prescribing

James H. Woods, PhD; Jonathan L. Katz, PhD; Gail Winger, PhD

JAMA. 1988;260(23):3476-3480.

Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

THE WIDESPREAD use of benzodiazepines has been a source of concern and debate, due in large part to the traditional association of "mood-altering" or sedating drugs with problems of abuse and dependence. Such problems have indeed been reported with the benzodiazepines, and the view has emerged that abuse and dependence might account for a substantial proportion of benzodiazepine use. On the other hand, many investigators1-5 have found that most use of benzodiazepines is appropriate to the prevalence of the medical and psychiatric conditions for which they are deemed effective. Physicians prescribing these drugs are faced with the need to weigh the potential risk to their patients against the drugs' demonstrated benefit in the treatment of anxiety and insomnia.

We have recently conducted a comprehensive review of the extensive experimental, clinical, and epidemiologic literature pertinent to the use and abuse of benzodiazepines.6 Our review indicates that these two predominant . . . [Full Text PDF of this Article]


Author Affiliations

From the Department of Pharmacology, The University of Michigan Medical School, Ann Arbor (Drs Woods and Winger); the Preclinical Pharmacology Branch, Addiction Research Center, National Institute on Drug Abuse, Baltimore (Dr Katz); and Department of Pharmacology and Experimental Therapeutics, University of Maryland School of Medicine, Baltimore (Dr Katz).


Footnotes

The views expressed herein are those of the authors and do not necessarily reflect the views of the agencies or institutions with which the authors are affiliated nor of the organizations providing funds for this work.

Reprint requests to M6322 Medical Science 1, The University of Michigan Medical School, Ann Arbor, MI 48109 (Dr Woods).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1988 American Medical Association. All Rights Reserved.